Medicago relies on an Australian plant that is a close relative to tobacco to develop vaccines. Medicago has been using plants to develop potential vaccines for more than two decades. It’s “at once exciting, and extremely frustrating” to be a small vaccine player vying to be taken seriously, Clark said. After focusing on the tobacco-adjacent plant, Medicago went public in 2006. The mRNA technology also has yet to generate a vaccine approved by regulators in the US or beyond.

Source: News 24 July 14, 2020 15:23 UTC